Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung

Modern Pathology

Volumn 25, Issue 12, 2012, Pages 1566-1573

  Grob, Tobias J ^a   Kannengiesser, Ivonne ^a   Tsourlakis, Maria C ^a   Atanackovic, Djordje ^a   Koenig, Alexandra M ^a   Vashist, Yogesh K ^a   Klose, Hans ^a   Marx, Andreas H ^a   Koops, Susan ^a   Simon, Ronald ^a   Izbicki, Jakob R ^a   Bokemeyer, Carsten ^a   Sauter, Guido ^a   Wilczak, Waldemar ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

adenocarcinoma of the lung; ERBB2 gene amplification; fluorescence in situ hybridization; HER2 expression; heterogeneity; large cell undifferentiated carcinoma of the lung; squamous cell carcinoma of the lung

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CLINICAL ARTICLE; CORRELATION ANALYSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE CLUSTER; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG LARGE CELL UNDIFFERENTIATED CARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; UNDIFFERENTIATED CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DNA, NEOPLASM; GENE AMPLIFICATION; GERMANY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPH NODES; MIDDLE AGED; RECEPTOR, ERBB-2; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 84870557498     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.125     Document Type: Article

References (35)

1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5:341-354. (Pubitemid 40637826)
2. Normanno N, Bianco C, Strizzi L, et al. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 2005;6:243-257. (Pubitemid 40667793)
3. Rabindran SK. Antitumor activity of HER-2 inhibitors. Cancer Lett 2005;227:9-23. (Pubitemid 41033088)
4. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 1999;17:2639-2648. (Pubitemid 29415219)
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792. (Pubitemid 32222155)
6. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726. (Pubitemid 34111379)
7. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
8. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743. (Pubitemid 46021510)
9. Bunn Jr PA, Helfrich B, Soriano AF, et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents Clin Cancer Res 2001;7:3239-3250. (Pubitemid 32963849)
10. Au NH, Cheang M, Huntsman DG, et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 2004;204:101-109. (Pubitemid 39214487)
11. Hirsch FR, Varella-Garcia M, Franklin WA, et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 2002;86:1449-1456. (Pubitemid 34548069)
12. Kwiatkowski DJ, Harpole Jr DH, Godleski J, et al. Molecular pathologic substaging in 244 stage I nonsmall- cell lung cancer patients: clinical implications J Clin Oncol 1998;16:2468-2477. (Pubitemid 28309043)
13. Nakamura H, Saji H, Ogata A, et al. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer. Int J Cancer 2003;103:61-66. (Pubitemid 35424206)
14. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005;23:5007-5018. (Pubitemid 46224007)
15. Pelosi G, Del Curto B, Dell'Orto P, et al. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. Int J Cancer 2005;113:101-108. (Pubitemid 39507316)
16. Tan D, Deeb G, Wang J, et al. HER-2/neu protein expression and gene alteration in stage I-IIIA nonsmall- cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn Mol Pathol 2003;12:201-211. (Pubitemid 37475228)
17. Pellegrini C, Falleni M, Marchetti A, et al. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription- PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res 2003;9:3645-3652. (Pubitemid 37169230)
18. Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004;15:19-27. (Pubitemid 38139598)
19. Langer CJ, Stephenson P, Thor A, et al. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol 2004;22: 1180-1187. (Pubitemid 41079829)
20. Andersson J, Linderholm B, Bergh J, et al. HER-2/neu (c-erbB-2) evaluation in primary breast carcinoma by fluorescent in situ hybridization and immunohistochemistry with special focus on intratumor heterogeneity and comparison of invasive and in situ components. Appl Immunohistochem Mol Morphol 2004;12:14-20. (Pubitemid 38332313)
21. Marx AH, Burandt EC, Choschzick M, et al. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol 2010;41: 1577-1585.
22. Sauter G, Moch H, Moore D, et al. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res 1993;53:2199-2203. (Pubitemid 23156798)
23. Bilous M, Osamura RY, Ruschoff J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2010;41:304-305; author reply 4-5.
24. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52: 797-805. (Pubitemid 351724903)
25. Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009;40:769-777.
26. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847. (Pubitemid 28331029)
27. World Health Organization Classification of Tumors. In: Travis WD, Brambilla E, Mu? ller-Hermelink HK, Harris CC(eds) Tumours of the Lung, Pleura, Thymus and Heart. IARC Press: Lyon; 2004, pp 9-124.
28. Sauter G, Lee J, Bartlett JM, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009; 27:1323-1333.
29. Adamo V, Franchina T, Adamo B, et al. Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study). Ann Oncol 2007;18 (Suppl 6) vi11-vi15.
30. Dawood S, Gonzalez-Angulo AM, Peintinger F, et al. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. Cancer 2007;110:1195-1200.
31. Simon R, Nocito A, Hubscher T, et al. Patterns of her-2/ neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93: 1141-1146. (Pubitemid 32780965)
32. Clamon G, Herndon J, Kern J, et al. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer 2005;103:1670-1675. (Pubitemid 40490028)
33. Zinner RG, Glisson BS, Fossella FV, et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 2004;44:99-110. (Pubitemid 38317266)
34. Ross HJ, Blumenschein Jr GR, Aisner J, et al. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res 2010;16:1938-1949.
35. Ferlay J, Shin H, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No 10 [Internet]; Lyon, France: International Agency for Research on Cancer 2010.